trending Market Intelligence /marketintelligence/en/news-insights/trending/hxavwxtwqrjbqq0fmnix8q2 content esgSubNav
In This List

Alnylam's neuro disease drug wins US FDA orphan drug status

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Alnylam's neuro disease drug wins US FDA orphan drug status

The U.S. Food and Drug Administration granted orphan drug designation to Alnylam Pharmaceuticals Inc.'s ALN-TTRsc02 for the treatment of a neurodegenerative disease known as transthyretin-mediated amyloidosis.

The designation is granted to medicines being developed to treat rare diseases or disorders that affect fewer than 200,000 people in the U.S.

The Cambridge, Mass.-based company's treatment is also designated as an orphan medicinal product in the EU.